The Clinical Impact of Hexanic Extract of Serenoa repens in Men with Prostatic Inflammation: A Post Hoc Analysis of a Randomized Biopsy Study
Open Access
- 30 March 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (4) , 957
Abstract
A randomized biopsy study showed that hexanic Serenoa repens (HESr) treatment resulted in prostatic inflammation reduction. This post-hoc analysis evaluated the clinical impact of HESr and investigated correlations between baseline parameters and treatment response. Patients were randomized to receive HESr 320mg/day for six months or no therapy. Assessment included International Prostate Symptoms Score (IPSS), prostate volume (PV), and maximum flow rate (Qmax). Baseline characteristics were recorded, including body mass index (BMI) and metabolic syndrome (MetS) components. In patients under α1-adrenoceptor antagonists (α1-blockers), the addition of HESr resulted in statistically significant IPSS improvement after 6 months (p = 0.006). IPSS remained stable in patients under a1-blockers only (p = 0.346). Patients treated only with HESr reported a significant IPSS amelioration (p = 0.001). In the control group of naïve patients, no significant IPSS change was detected (p = 0.298). Baseline PV showed fair correlation (r = −0.20) with inflammation reduction in the HESr patients. BMI (r = 0.40), diabetes mellitus (r = 0.40), and PV (r = 0.23) showed fair correlation with Qmax increase but without reaching statistical significance. MetS (p = 0.06) was an influent biomarker for Qmax improvement. Treatment with HESr (as monotherapy or add-on therapy to a-blockers) may improve urinary symptoms in terms of IPSS in patients with prostatic inflammation.Keywords
This publication has 16 references indexed in Scilit:
- Anti-Inflammatory and Anticancer Properties of Bioactive Compounds from Sesamum indicum L.—A ReviewMolecules, 2019
- The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy studyWorld Journal of Urology, 2018
- Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstructionProstate Cancer and Prostatic Diseases, 2018
- Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled TrialsEuropean Urology Focus, 2016
- Therapeutic Approach: The Importance of Controlling Prostatic InflammationEuropean Urology Supplements, 2013
- Genista sessilifolia DC. extracts induce apoptosis across a range of cancer cell linesCell Proliferation, 2013
- Metabolic syndrome and lower urinary tract symptoms: the role of inflammationProstate Cancer and Prostatic Diseases, 2012
- The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of InflammationEuropean Urology, 2011
- The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE TrialEuropean Urology, 2008
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005